Lessons from TGN-1412 - the impact on phase I clinical trials.
Weerasekera
Natasha
N
Medicines and Healthcare products Regulatory Agency (MHRA), Information Centre, 10-2 Market Towers, 1 Nine Elms Lane, London, SW8 5NQ, UK.
Hudson
Ian
I
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000633:toxicity; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000633:toxicity; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D005060:Europe; D006801:Humans; D008252:Macaca fascicularis
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C509303:TGN-1412